Ayyampuzha

Researchers are evaluating the safety and effectiveness of brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine AVD in adults with untreated stage 3 or 4 classical Hodgkin Lymphoma. This phase 4 study focuses on how well this combination works and monitors any side effects experienced by participants. The study is open-label and involves patients from India with confirmed Hodgkin Lymphoma. Participants will receive brentuximab vedotin at a dose of 1.2 mgkg through intravenous infusion on days 1 and 15 of each 28-day treatment cycle. Each infusion is given within one hour after receiving doxorubicin, vinblastine, and dacarbazine infusions. This treatment is provided for up to six cycles, lasting about six months in total. During the study, participants will have heart function tested by echocardiography and lung function assessed by pulmonary function tests. Researchers will review safety by tracking adverse events for up to 40 weeks and assess how well the treatment works by measuring remission rates and survival outcomes. After finishing treatment, participants will have a final health check two months later to monitor their status and overall well-being.